185 related articles for article (PubMed ID: 37942831)
21. From MASH to HCC: the role of Gas6/TAM receptors.
Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M
Front Immunol; 2024; 15():1332818. PubMed ID: 38298195
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis.
Asakawa M; Itoh M; Suganami T; Sakai T; Kanai S; Shirakawa I; Yuan X; Hatayama T; Shimada S; Akiyama Y; Fujiu K; Inagaki Y; Manabe I; Yamaoka S; Yamada T; Tanaka S; Ogawa Y
Sci Rep; 2019 Dec; 9(1):19601. PubMed ID: 31862949
[TBL] [Abstract][Full Text] [Related]
23. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
[TBL] [Abstract][Full Text] [Related]
24. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
Etzion O; Bareket-Samish A; Yardeni D; Fishman P
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201
[TBL] [Abstract][Full Text] [Related]
25. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
26. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
28. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
29. Curcumin preconditioned mesenchymal stem cells derived exosomes transplantation ameliorate and protect against non- alcoholic steatohepatitis by regulation the expression of key genes of inflammation and oxidative stress.
Tawfeek GA; Kasem HA
Transpl Immunol; 2023 Jun; 78():101837. PubMed ID: 37031771
[TBL] [Abstract][Full Text] [Related]
30. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
31. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
32. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
33. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
34. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
[TBL] [Abstract][Full Text] [Related]
35. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
36. Co-targeting ASK1 and THRβ synergistically improves steatohepatitis and fibrosis in a MASH animal model.
Shang S; Wan Q; Chen F; Hu J
Biochem Biophys Res Commun; 2024 Apr; 705():149739. PubMed ID: 38460439
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
38. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
39. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
40. Altered Cell to Cell Communication, Autophagy and Mitochondrial Dysfunction in a Model of Hepatocellular Carcinoma: Potential Protective Effects of Curcumin and Stem Cell Therapy.
Tork OM; Khaleel EF; Abdelmaqsoud OM
Asian Pac J Cancer Prev; 2015; 16(18):8271-9. PubMed ID: 26745072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
